Overcoming drug resistance in cervical cancer: Chemosensitizing agents and targeted therapies

Jalil, Anum; Wert, James; Farooq, Aimen; Ahmad, Sarfraz

doi:10.1016/b978-0-12-824299-5.00010-1

Cited by 1 publication

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most effective chemotherapeutic agent used in cervical cancer treatment is Cisplatin, which can be used either as a single agent or in combination with other therapeutic agents, e.g. 5-Fluorouracil 29 . More advanced stages of cervical cancer are treated by chemotherapy, including metastatic disease, as well as patients with persistent, or recurrent disease.…”

Section: Chemoresistance In Cervical Cancer Therapymentioning

confidence: 99%

“…One of the main obstacles in the treatment of late-stage cervical cancer is resistance which develops to chemotherapeutic agents 31 . An increase in the number of available chemotherapeutic agents has resulted in increased resistance in cancer cells as more exposure to medications makes tumour cells more prone to developing drug resistance which subsequently leads to widespread metastasis 29 .…”

Section: Chemoresistance In Cervical Cancer Therapymentioning

confidence: 99%

“…Cisplatin interacts with DNA molecules to form cross-linked DNA "adducts" which in turn activate several downstream molecular pathways including p53 and MAPK, ultimately resulting in apoptosis 29 . Chemoresistance arises in cancer cells via the downregulation of tumour suppressors and the stabilization or activation of cell survival factors 32 including increased DNA repair, decreased uptake of drug into the tumour cells and increased inactivation of drug 29 . These mechanisms lead to less apoptosis in cancer cells, resulting in unchecked tumour replication and spread of malignancy 33,34 .…”

Section: Chemoresistance In Cervical Cancer Therapymentioning

confidence: 99%

See 2 more Smart Citations

The Development of Locoregional Therapies as a Strategy for Reducing Cervical Cancer Mortality in Low to Middle Income Countries.

Chituku

Jones

Phillips

2022

Preprint

View full text Add to dashboard Cite

Early detection concomitant with appropriate treatment intervention for pre-invasive cervical cancer has proved effective in the ‘war on cervical cancer’ in the developed world. Unfortunately, these advances have not been mirrored in the developing world, where incidence and mortality rates are currently approximately 90% of the world’s burden. Due to economic, infrastructure and skilled personnel constraints, the impact of cytology screening as a method for early detection and reducing mortality rates from cervical cancer is lower. Typically, women present with advanced disease that is difficult to treat because of de novo and pharmacokinetic resistance. Whilst the HPV vaccine is a welcome development in the fight against cervical cancer, for women who are outside the target age of vaccination, or indeed do not have access to vaccination, screening remains the only form of protection. Current excisional treatments available for cervical dysplasia are effective but have limitations, including increased incidence of obstetric complications and risk of recurrence. This is a particular issue in cases of HIV, which is endemic in the regions most affected by cervical cancer. Therefore, early detection combined with early treatment is an attractive strategy to reduce the number of women presenting with drug resistant disease in developing countries where cytology screening and vaccination services are poorly developed. This review makes the case for developing a locoregional treatment therapy for cervical dysplasia which could be incorporated into a cervical cancer screening strategy in a rural setting within a developing country.

show abstract

Section: Chemoresistance In Cervical Cancer Therapymentioning

confidence: 99%

Section: Chemoresistance In Cervical Cancer Therapymentioning

confidence: 99%